Spallotta F, Illi B
Biomedicines. 2024; 12(11).
PMID: 39595195
PMC: 11591585.
DOI: 10.3390/biomedicines12112631.
Pol S, Liljenberg S, Barr J, Simon G, Wong-Dilworth L, Paterson D
RSC Chem Biol. 2024; .
PMID: 39444693
PMC: 11494418.
DOI: 10.1039/d4cb00184b.
Tataranu L, Turliuc S, Rizea R, Dricu A, Alexandru O, Staicu G
Curr Issues Mol Biol. 2024; 46(7):6903-6939.
PMID: 39057054
PMC: 11275428.
DOI: 10.3390/cimb46070412.
Mironova E, Molinas S, Pozo V, Bandyopadhyay A, Lai Z, Kurmashev D
Cancers (Basel). 2024; 16(11).
PMID: 38893160
PMC: 11171327.
DOI: 10.3390/cancers16112041.
Watanabe K, Seki N
Int J Mol Sci. 2024; 25(2).
PMID: 38255825
PMC: 10815806.
DOI: 10.3390/ijms25020752.
The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer.
Fang Q
Cancers (Basel). 2024; 16(2).
PMID: 38254819
PMC: 10814553.
DOI: 10.3390/cancers16020331.
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
Leske H, Camenisch Gross U, Hofer S, Neidert M, Leske S, Weller M
Acta Neuropathol Commun. 2023; 11(1):139.
PMID: 37641156
PMC: 10463744.
DOI: 10.1186/s40478-023-01622-w.
A multi-functional hypoxia/esterase dual stimulus responsive and hyaluronic acid-based nanomicelle for targeting delivery of chloroethylnitrosouea.
Li D, Ren T, Ge Y, Wang X, Sun G, Zhang N
J Nanobiotechnology. 2023; 21(1):291.
PMID: 37612719
PMC: 10464291.
DOI: 10.1186/s12951-023-02062-3.
CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N, Biteghe F, Malindi Z, Huysamen A, Karaan M, Hardcastle N
J Cancer Res Clin Oncol. 2023; 149(13):12203-12225.
PMID: 37432459
PMC: 10465649.
DOI: 10.1007/s00432-023-05031-3.
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Brawanski K, Sprung S, Freyschlag C, Hoeftberger R, Strobel T, Haybaeck J
Int J Mol Sci. 2023; 24(7).
PMID: 37047153
PMC: 10094528.
DOI: 10.3390/ijms24076184.
The "Superoncogene" Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme.
Cencioni C, Scagnoli F, Spallotta F, Nasi S, Illi B
Int J Mol Sci. 2023; 24(4).
PMID: 36835628
PMC: 9966483.
DOI: 10.3390/ijms24044217.
Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway.
Rahman M, Engelsen A, Sarowar S, Bindesboll C, Birkeland E, Goplen D
Front Cell Dev Biol. 2023; 10:1022191.
PMID: 36619857
PMC: 9814514.
DOI: 10.3389/fcell.2022.1022191.
Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research.
Ahmed M, Semreen A, El-Huneidi W, Bustanji Y, Abu-Gharbieh E, Alqudah M
Int J Mol Sci. 2023; 24(1).
PMID: 36613792
PMC: 9820403.
DOI: 10.3390/ijms24010348.
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A, Gusyatiner O, Bady P, Buri M, Lomazzi R, Chiesi D
Cell Death Dis. 2022; 13(12):1037.
PMID: 36513631
PMC: 9747918.
DOI: 10.1038/s41419-022-05497-y.
NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
Tsuji S, Nakamura S, Shoda K, Yamada T, Shimazawa M, Nakayama N
J Neurooncol. 2022; 160(2):375-388.
PMID: 36308592
DOI: 10.1007/s11060-022-04154-w.
The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma.
Malindi Z, Barth S, Abrahamse H
Biomedicines. 2022; 10(9).
PMID: 36140259
PMC: 9495799.
DOI: 10.3390/biomedicines10092158.
Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine.
Crake R, Burgess E, Wiggins G, Magon N, Das A, Vissers M
Sci Rep. 2022; 12(1):14845.
PMID: 36050369
PMC: 9436949.
DOI: 10.1038/s41598-022-19032-8.
Molecular and Circulating Biomarkers in Patients with Glioblastoma.
Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S
Int J Mol Sci. 2022; 23(13).
PMID: 35806478
PMC: 9267689.
DOI: 10.3390/ijms23137474.
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S, Sule A, Sundaram R, Bindra R
Sci Rep. 2022; 12(1):5827.
PMID: 35388070
PMC: 8987098.
DOI: 10.1038/s41598-022-09614-x.
A combination of direct reversion and nucleotide excision repair counters the mutagenic effects of DNA carboxymethylation.
Aloisi C, Escher N, Kim H, Geisen S, Fontana G, Yeo J
DNA Repair (Amst). 2022; 110:103262.
PMID: 35030424
PMC: 9232693.
DOI: 10.1016/j.dnarep.2021.103262.
